Wednesday, October 10, 2018 – Poster Session 1 – 5:00 – 7:00 PM
Here are Steven’s Top 10 poster topics at ECTRIMS for Wednesday, October 10, 2018. Read More
Latest News
Laquinimod program cancelled in MS
September 6, 2018Teva Pharmaceuticals has announced that it will no longer pursue the commercial development of laquinimod, a small-molecule aryl hydrocarbon receptor activator, in neurodegenerative diseases. The development and commercialization rights will revert back to Active Biotech, the company that originated the molecule. Read More
Canadian real-world study of aripiprazole LAI in schizophrenia
August 23, 2018POSTER DISCUSSION
Presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, Florida, May 29 – June 1, 2018
The first Canadian naturalistic study in patients with schizophrenia has reported high rates of remission rates and low rates of relapse with long-acting aripiprazole over a one-year period (Oluboka et al. ASCP 2018; abstract). Read More
Heart disease associated with atrophy in MS
August 15, 2018The University of Buffalo MS group has reported that comorbid cardiovascular disease appears to contribute to more rapid brain tissue loss in patients with multiple sclerosis (Jakimovski et al. Eur J Neurol 2018; epublished August 13, 2018). Read More